Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CLOSER trial: a multi-center study on the clinical safety and effectiveness of CloserTM VSS, a novel resorbable transfemoral vascular access sealing system.
Wong SC, Gammon R, Bachinsky W, O'Shaughnessy C, Leimbach W, Bernardo N, Cavros N, Jaff MR, Liu PY, Bergman G. Wong SC, et al. Among authors: bachinsky w. Catheter Cardiovasc Interv. 2017 Nov 1;90(5):798-805. doi: 10.1002/ccd.27241. Epub 2017 Aug 23. Catheter Cardiovasc Interv. 2017. PMID: 28833996 Clinical Trial.
A randomized comparison of a novel bioabsorbable vascular closure device versus manual compression in the achievement of hemostasis after percutaneous femoral procedures: the ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial).
Wong SC, Bachinsky W, Cambier P, Stoler R, Aji J, Rogers JH, Hermiller J, Nair R, Hutman H, Wang H; ECLIPSE Trial Investigators. Wong SC, et al. Among authors: bachinsky w. JACC Cardiovasc Interv. 2009 Aug;2(8):785-93. doi: 10.1016/j.jcin.2009.06.006. JACC Cardiovasc Interv. 2009. PMID: 19695549 Free article. Clinical Trial.
Proper patient selection yields significant and sustained reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: long-term results from the HERCULES trial.
Chrysant GS, Bates MC, Sullivan TM, Bachinsky WB, Popma JJ, Peng L, Omran HL, Jaff MR; HERCULES Investigators. Chrysant GS, et al. J Clin Hypertens (Greenwich). 2014 Jul;16(7):497-503. doi: 10.1111/jch.12341. Epub 2014 Jun 7. J Clin Hypertens (Greenwich). 2014. PMID: 24909590 Free PMC article. Clinical Trial.
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Mauri L, et al. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16. N Engl J Med. 2014. PMID: 25399658 Free PMC article. Clinical Trial.
S.M.A.R.T. self-expanding nitinol stent for the treatment of atherosclerotic lesions in the superficial femoral artery (STROLL): 1-year outcomes.
Gray WA, Feiring A, Cioppi M, Hibbard R, Gray B, Khatib Y, Jessup D, Bachinsky W, Rivera E, Tauth J, Patarca R, Massaro J, Stoll HP, Jaff MR; STROLL Study Investigators. Gray WA, et al. Among authors: bachinsky w. J Vasc Interv Radiol. 2015 Jan;26(1):21-8. doi: 10.1016/j.jvir.2014.09.018. Epub 2014 Nov 15. J Vasc Interv Radiol. 2015. PMID: 25454735 Clinical Trial.
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Kereiakes DJ, et al. JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. JAMA. 2015. PMID: 25781440 Free PMC article. Clinical Trial.
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Yeh RW, et al. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. JAMA. 2016. PMID: 27022822 Free PMC article. Clinical Trial.
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP. Krishnan P, et al. Circulation. 2017 Sep 19;136(12):1102-1113. doi: 10.1161/CIRCULATIONAHA.117.028893. Epub 2017 Jul 20. Circulation. 2017. PMID: 28729250 Free PMC article. Clinical Trial.
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Lesions: 1-Year Results From the Disrupt CAD III Study.
Kereiakes DJ, Hill JM, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW; Disrupt CAD III Investigators. Kereiakes DJ, et al. Among authors: bachinsky w. J Soc Cardiovasc Angiogr Interv. 2022 Jan 30;1(1):100001. doi: 10.1016/j.jscai.2021.100001. eCollection 2022 Jan-Feb. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39130140 Free PMC article.
57 results